PREVENT equations

There are 29 papers on PREVENT equations in aging research: 1 trial and 19 observational studies in people, 7 reviews. The newest story, Nov 18, 2026: “Tighter blood pressure control linked to lower cardiovascular risk”.

Biomarker

29 papers study it63 more mention it12 findings

38 new papers in 30 daysSee all 92 papers on PREVENT equations

At a glance

PREVENT equations predict cardiovascular disease and mortality in human cohorts, including cardiovascular disease in breast cancer survivors and cardiovascular mortality in people without baseline cardiovascular disease. Scores are associated with coronary plaque burden but show no clear link with low-density noncalcified plaque. A review describes lower treatment eligibility than with the PCE.

12 findings in 9 papers from 2025 to 2026, 4 of them since April 2026

“Harrell’s C-index for the PREVENT Base equation was 0.764 (95% CI = 0.761–0.767) in NH White, 0.773 (95% CI = 0.765–0.779) in NH Asian, and 0.757 (95% CI = 0.733–0.780) in NH NHPI adults”
Evaluation of PREVENT Equations for Estimating Cardiovascular Disease Risk in Individual Asian American and Native Hawaiian and Pacific Islander GroupsAHA Scientific Sessions 2025 abstract2025doi:10.1161/circ.152.suppl_3.4359477
  • Human trial1
  • Humans19
  • In silico1

Effects

2

Treatment eligibility

downin humans1

1 study
  1. PREVENT equations decrease treatment eligibility in humans (versus the PCE).

    “It often lowers estimated risk and modeled eligibility for statin or antihypertensive therapy versus the PCE.”

    Reviewversus the PCE

    The PREVENT Equations Evidence Appraisal of Validation and Clinical Implications

    Current problems in cardiology

Low-density non-calcified plaque

no changein humans1

1 study
  1. PREVENT equations were not clearly linked with low-density non-calcified plaque in humans (p=0.15).

    “When analyzing the PREVENT score as a continuous variable, higher scores were associated with greater TPV, CP, and NCP (all p<0.001, Table 1 ), but not LDNCP (p=0.15).”

    Humanscoronary arteryn = 525

    Associations of Predicted CVD risk by the PREVENT Equation with AI-analyzed Coronary Atherosclerotic Plaque Characteristics

    AHA Scientific Sessions 2025 abstract

More on Low-density non-calcified plaque

Associations

4

Cardiovascular disease

upin humans4OR 2.94

4 studies
  1. PREVENT equations predict cardiovascular disease in humans (subgroup without prior CV disease) (C-statistic 0.698).

    “while the 10-year UACR-enhanced AHA PREVENT equation achieved 0.698 (p<0.001).”

    Humanssubgroup without prior CV diseasemedian 10.6 yearsn = 2,124

    Cardiovascular Risk Prediction with the Kidney Failure Risk Equation in the Chronic Renal Insufficiency Study

    Kidney360

  2. PREVENT equations are associated with cardiovascular disease in humans (intermediate-high (≥7.5% per AHA) 10-year PREVENT absolute risk) (12.11-fold higher odds).

    “Those with 10-year PREVENT absolute risk defined as intermediate-high (≥7.5% per AHA) had 12.11-fold higher odds (P < .001).”

    Humansintermediate-high (≥7.5% per AHA) 10-year PREVENT absolute riskmalesn = 737

    Cardiovascular disease risk among long-term testicular cancer survivors following contemporary cisplatin-based chemotherapy

    Journal of the National Cancer Institute

  3. PREVENT equations predict cardiovascular disease in humans (per 5% increase in 10-year PREVENT risk) (OR 2.94, 95% CI 1.99-4.35).

    “each 5% increase in 10-year PREVENT risk conferred 2.94-fold odds (95%CI = 1.99-4.35, P < .001) of incident CVD”

    Humansper 5% increase in 10-year PREVENT riskmalesn = 737

    Cardiovascular disease risk among long-term testicular cancer survivors following contemporary cisplatin-based chemotherapy

    Journal of the National Cancer Institute

  4. PREVENT equations predict cardiovascular disease in humans (C-index 0.773 (95% CI 0.765–0.779)).

    “Harrell’s C-index for the PREVENT Base equation was 0.764 (95% CI = 0.761–0.767) in NH White, 0.773 (95% CI = 0.765–0.779) in NH Asian, and 0.757 (95% CI = 0.733–0.780) in NH NHPI adults”

    Humans10 yearsn = 542,848

    Evaluation of PREVENT Equations for Estimating Cardiovascular Disease Risk in Individual Asian American and Native Hawaiian and Pacific Islander Groups

    AHA Scientific Sessions 2025 abstract

  5. PREVENT equations predict cardiovascular disease in humans (breast cancer survivors) (AUCt 0.74 (95% CI 0.71-0.77)).

    “The AUC t (95% CI) of PREVENT equations were 0.74 (0.71-0.77) for CVD”

    Humansbreast cancer survivorsmedian follow-up of 4.5 yearsfemalesn = 10,403

    Performance of the PREVENT CVD risk prediction score in breast cancer survivors

    AHA Scientific Sessions 2025 abstract

More on Cardiovascular disease

Cardiovascular mortality

upin humans2

2 studies
  1. PREVENT equations are linked with a higher risk of cardiovascular mortality in humans (without baseline cardiovascular disease).

    “and cardiovascular mortality (HR, 1.66; 95% CI, 1.501.84).”

    Humanswithout baseline cardiovascular diseasen = 1,516

    Assessing Differences Between Epigenetic versus Chronologic Age for Cardiovascular Risk Assessments in the United States

    Circulation. Population health and outcomes

  2. PREVENT equations predict cardiovascular mortality in humans (free of CVD) (AUC 0.77 vs 0.71).

    “The PREVENT equation exhibited better discrimination (AUCt=10 (95% CI): 0.77 (0.71, 0.83)) than the PCE (0.71 (0.64, 0.78))”

    Humansfree of CVDn = 1,998

    Prognostic value of PREVENT, PCE, and social determinants of health for cardiovascular mortality in the Healthy Aging in Neighborhoods of Diversity across the Life Span (HANDLS) study

    BMC public health

Mortality

upin humans2HR 1.57

2 studies
  1. PREVENT equations are linked with a higher risk of mortality in humans (without baseline cardiovascular disease) (HR, 1.57; 95% CI, 1.45-1.70).

    “Each 5-percentage-point increase in chronologic PREVENT risk was associated with all-cause mortality (HR, 1.57; 95% CI, 1.45-1.70)”

    Humanswithout baseline cardiovascular diseasen = 1,516

    Assessing Differences Between Epigenetic versus Chronologic Age for Cardiovascular Risk Assessments in the United States

    Circulation. Population health and outcomes

  2. PREVENT equations predict mortality in humans.

    “PREVENT improved only the prediction of all-cause mortality beyond CAC”

    Humansmedian follow-up of 3.7 yearsn = 1,912

    PREVENT in the 75-and-older population and additional prognostic value of coronary artery calcium: the Atherosclerosis Risk in Communities (ARIC) study

    AHA Scientific Sessions 2025 abstract

Coronary plaque burden

upin humans1

1 study
  1. PREVENT equations are associated with coronary plaque burden in humans (p<0.001 for trend).

    “Total, calcified and non-calcified plaque burden, stenosis severity, and remodeling index increased across higher 10-year total CVD risk categories (p<0.001 for trend”

    Humanscoronary arteryn = 525

    Associations of Predicted CVD risk by the PREVENT Equation with AI-analyzed Coronary Atherosclerotic Plaque Characteristics

    AHA Scientific Sessions 2025 abstract

More on Coronary plaque burden

How this record changed

  1. Summary rewritten as its findings changed.

    As it read before

    PREVENT equations predict cardiovascular disease in human cohorts, including female breast cancer survivors, and cardiovascular mortality in people initially free of cardiovascular disease. Scores are associated with coronary plaque burden but show no clear link with low-density noncalcified plaque; a review describes lower treatment eligibility than with the PCE.

  2. Summary rewritten as its findings changed.

    As it read before

    A human study reports cardiovascular-disease prediction by PREVENT equations with a C-statistic of 0.698 in people without prior cardiovascular disease. Another associates PREVENT estimates with overall and cardiovascular mortality in people without baseline cardiovascular disease. A review describes reduced treatment eligibility compared with the PCE.

  3. Summary written from the findings.

Latest

Dec 2025: 0Jan 2026: 3Feb 2026: 5Mar 2026: 3Apr 2026: 1May 2026: 0Jun 2026: 1Jul 2026: 6Aug 2026: 11Sep 2026: 11Oct 2026: 11Nov 2026: 2678 papers in 12 months
Hypertension

Tighter blood pressure control linked to lower cardiovascular risk

Compared with usual care, hazard ratios—relative measures of cardiovascular risk over time—were 0.53, 0.58 and 0.60 in low-, intermediate- and high-risk adults.Compared with usual care, hazard ratios—relative measures of cardiovascular risk over time—were 0.53, 0.58 and 0.60 in low-, intermediate- and high-risk adults.

Non-randomized trial in 21,872 peopleCardiovascular disease
medRxiv

Obesity and diabetes rose as smoking fell among US adults

From 1999–2000 to 2021–2023, obesity rose from 47.4% to 57.2% and diabetes from 8.2% to 12.7%, while smoking declined.From 1999–2000 to 2021–2023, obesity rose from 47.4% to 57.2% and diabetes from 8.2% to 12.7%, while smoking declined.

Preprint: cross-sectional · 60,199 peopleDiabetes mellitus
AHA Scientific Sessions 2026 Abstract

Inflammation protein may help refine heart disease risk estimates

The inflammation marker interleukin-6 separated event rates between people reassigned to higher and lower risk groups by 1.15 per 1,000 person-years, versus 0.54 for…The inflammation marker interleukin-6 separated event rates between people reassigned to higher and lower risk groups by 1.15 per 1,000 person-years, versus 0.54 for C-reactive protein.

Cohort · 32,920 peopleBiomarkers

See all 92 papers on PREVENT equations